StreetInsider.com News Articles

Form DEF 14A Entera Bio Ltd. For: Oct 14

Wed, 14 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261014/27187143.html

Entera Bio shares Phase 2 data and Phase 3 design for oral PTH tablet

Tue, 13 Oct 2026 07:01:05 -0400

Entera Bio Ltd. (NASDAQ: ENTX) presented post-hoc Phase 2 data and its Phase 3 study design for EB613, an oral PTH(1-34) tablet being developed for postmenopausal osteoporosis, at the American Society for Bone and Mineral Research Annual Meeting held October 9-12, 2026, in Boston.

The post-hoc analysis from the Phase 2 trial examined outcomes in postmenopausal women with baseline T-scores of ≤-2.5 versus those with T-scores of >-2.5. Among women with T-scores of ≤-2.5 treated with EB613 2.5 mg daily, placebo-adjusted bone mineral density increases at six months were 4.23% at the total hip and 4.22% at the lumbar spine. Women

Entera Bio shares Phase 2 EB613 bone density data at ASBMR meeting

Tue, 13 Oct 2026 07:01:01 -0400

Entera Bio Ltd. (NASDAQ: ENTX) presented post-hoc Phase 2 data and a Phase 3 study design for its oral osteoporosis tablet candidate EB613 at the American Society for Bone and Mineral Research Annual Meeting, held October 9-12, 2026, in Boston.

The post-hoc analysis examined results from a previously completed Phase 2 trial that randomized 161 postmenopausal women to placebo or one of four EB613 dose levels for six months. The analysis focused on participants receiving EB613 2.5 mg daily, comparing outcomes by baseline T-score.

Women with baseline T-scores of ≤-2.5, indicating osteoporosis, showed mean placebo-adjusted bone mineral density increases of 4.23% at

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS

Tue, 13 Oct 2026 07:00:00 -0400

Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia)

These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study

TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced data

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS

Tue, 13 Oct 2026 07:00:00 -0400

TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced data

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS

Tue, 13 Oct 2026 07:00:00 -0400

TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced data

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at AS

Tue, 13 Oct 2026 07:00:00 -0400

TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced data

Entera Bio to present EB613 Phase 3 study design at ASBMR meeting

Thu, 08 Oct 2026 08:00:18 -0400

Entera Bio Ltd. (NASDAQ: ENTX) announced that a presentation of the clinical study design for its planned Phase 3 trial of EB613, an oral PTH(1-34) tablet for osteoporosis, has been accepted as a late-breaking poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting in Boston, Massachusetts, running October 9-12, 2026.

The presentation, titled "EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design," is scheduled for Sunday, October 11, 2026, from 2:00 to 3:30 p.m. ET (Presentation Number: Sun-522). It will be led by Dr. Felicia Cosman, Professor

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

Thu, 08 Oct 2026 08:00:00 -0400

TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.

The additional presentation, titled “EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

Thu, 08 Oct 2026 08:00:00 -0400

The additional presentation, titled “EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.

Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Form 8-K Entera Bio Ltd. For: Oct 06